Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans

This article, published in The New England Journal of Medicine, discusses the methods and results of two studies conducted in Africa to evaluate a new meningococcal A conjugate vaccine. The conclusion of the studies is that the new vaccine has a safety profile similar to that of a licensed polysaccharide vaccine but elicits a significantly stronger and more persistent response from functional antibodies against group A meningococcus, when tested in Africans between 1 and 29 years of age.

Author(s): Sow SO, Okoko BJ, Diallo A, et al.

Published: 2011

  • Visit web page (English)

    (Located at www.nejm.org)

    Citation: Sow SO, Okoko BJ, Diallo A, et al. Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. The New England Journal of Medicine. 2011;364(24):2293-2304.